open access

Vol 4, No 3 (2018)
Przypadki kliniczne
Published online: 2018-10-26
Get Citation

Renal amyloidosis secondary to rheumatoid arthritis effectively treated with tocilizumab

Dorota Sikorska, Włodzimierz Samborski
DOI: 10.5603/FR.2018.0006
·
Forum Reumatologiczne 2018;4(3):184-186.

open access

Vol 4, No 3 (2018)
Przypadki kliniczne
Published online: 2018-10-26

Abstract

Kidney amyloidosis is one of the most serious potential complication of chronic inflammatory disorders, including rheumatoid arthritis. Interleukin-6 blockade is frequently effective in rheumatic disease, however, there are only few published data on its use in AA amyloidosis. Here, we report a case of patient with rheumatoid arthritis complicated by nephrotic syndrome due to secondary type A amyloidosis successfully treated with tocilizumab.

Forum Reumatol. 2018, tom 4, nr 3: 184–186

Abstract

Kidney amyloidosis is one of the most serious potential complication of chronic inflammatory disorders, including rheumatoid arthritis. Interleukin-6 blockade is frequently effective in rheumatic disease, however, there are only few published data on its use in AA amyloidosis. Here, we report a case of patient with rheumatoid arthritis complicated by nephrotic syndrome due to secondary type A amyloidosis successfully treated with tocilizumab.

Forum Reumatol. 2018, tom 4, nr 3: 184–186

Get Citation

Keywords

rheumatoid arthritis; kidney amyloidosis; tocilizumab

About this article
Title

Renal amyloidosis secondary to rheumatoid arthritis effectively treated with tocilizumab

Journal

Forum Reumatologiczne

Issue

Vol 4, No 3 (2018)

Pages

184-186

Published online

2018-10-26

DOI

10.5603/FR.2018.0006

Bibliographic record

Forum Reumatologiczne 2018;4(3):184-186.

Keywords

rheumatoid arthritis
kidney amyloidosis
tocilizumab

Authors

Dorota Sikorska
Włodzimierz Samborski

References (14)
  1. Mohamed N, Nasr SH. Renal Amyloidosis. Surg Pathol Clin. 2014; 7(3): 409–425.
  2. Wang YH, Zhang YG. Amyloid and immune homeostasis. Immunobiology. 2017.
  3. Cohen A, Jones L. Amyloidosis. Current Opinion in Rheumatology. 1991; 3(1): 125–138.
  4. Horak P, Smrzova A, Krejci K, et al. Renal manifestations of rheumatic diseases. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013; 157(2): 98–104.
  5. Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012; 142: w13580.
  6. Król E, Perkowska-Ptasińska A, Oko A. Kidney involvement in rheumatoid arthritis – diagnostic and management recommendations. Nefrol Dial Pol. 2016; 20: 127–133.
  7. Mittal T, Rathi M. Rheumatological diseases and kidneys: a nephrologist's perspective. Int J Rheum Dis. 2014; 17(8): 834–844.
  8. Shetty A, Hanson R, Korsten P, et al. Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther. 2014; 8: 349–364.
  9. Smolen JS, Landewe R, Bijlsma J. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the rheumatic diseases. 2017; 76(6): 960–977.
  10. Courties A, Grateau G, Philippe P, et al. Club Rhumatismes Inflammation and the REGATE Registry. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid. 2015; 22(2): 84–92.
  11. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006; 54(9): 2997–3000.
  12. Vinicki JP, De Rosa G, Laborde HA. Renal amyloidosis secondary to rheumatoid arthritis: remission of proteinuria and renal function improvement with tocilizumab. J Clin Rheumatol. 2013; 19(4): 211–213.
  13. Miyagawa I, Nakayamada S, Saito K, et al. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis. Mod Rheumatol. 2014; 24(3): 405–409.
  14. Uda H, Saiki O. Tocilizumab postpones the start of hemodialysis compared to conventional oral treatment in amyloid A amyloidosis patients with advanced renal insufficiency by suppressing serum SAA levels. Amyloid. 2017; 24(1): 62–63.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl